Please login to the form below
Licensing deals
This page shows the latest Licensing deals news and features for those working in and with pharma, biotech and healthcare.
Gilead swoops on Forty Seven with $4.9bn all-cash deal
Takeover is latest in a string of billion-plus deals signed by Gilead. ... The takeover is the latest in a string of big billion dollar-plus licensing and acquisition deals signed by Gilead since the start of 2019 under new chief executive Daniel
Latest news
-
Takeda buys coeliac disease partner PvP Biologics after phase 1 win
There has been a flurry of licensing deals in the coeliac disease area in recent months, including deals between GlaxoSmithKline and Sitari and Roche/Genentech and Parvus, as drugmakers eye a
-
Boehringer bolsters NASH pipeline with Enleofen link-up
It’s the first licensing deal for the company and is also thought to be the largest ever agreed by a Singapore biotech, with Boehringer agreeing to pay up to 1bn ( ... a series of licensing deals as well as its in-house research.
-
AstraZeneca launches $1bn Chinese investment fund
generic products, over a ten-year period, and has agreed licensing deals for three early-stage cancer drugs with Chinese biotech firms.
-
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug
Has potential in cardiovascular and metabolic diseases. Pfizer has bolted on an antisense drug with potential in cardiovascular and metabolic diseases to its pipeline via a licensing deal with Ionis’ Akcea ... affiliate. The big pharma – which has
-
Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder
Lundbeck hasn’t traditionally been a particularly active player in M&A, preferring to rely mainly on its in-house R&D and smaller-scale licensing deals, but has stepped up ... the pace of deals under new CEO Deborah Dunsire (pictured below).
More from news
Approximately 2 fully matching, plus 86 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
the pipeline, the use of technology in medicine is expected to grow and so are the associated deals, mergers and acquisitions. ... They also can help identify collaboration opportunities including partnerships, licensing deals and merger or acquisition
-
20 for 2020 – Five pharma leaders to watch in 2020
returns. That includes an exit from areas like neurology – which predates Bourla’s appointment as CEO but was set up while he was COO – and a series of bolt-on deals ... Meanwhile, Galapagos looks set to continue adding to its pipeline through
-
A market-adapted agile approach to launch excellence
Furthermore, increases. in region or market-specific licensing deals for launch products have led companies to devolve to region-specific cross-functional teams for tailored launch preparation, allowing different thinking to
-
The changing nature of approvals – what does the future hold?
Mega-mergers are also becoming less frequent; instead, we’re seeing fewer but larger deals. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the
-
Deal Watch October 2018
Licensing &. research. collaboration. $550m. Novartis/. Mylan. TOBI Podhaler and TOBI solution for cystic fibrosis. ... Licensing &. collaboration. $40m. All deals are for worldwide rights unless stated otherwise:.
More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.
Latest appointments
-
Ablynx appoints Markus Ewert as chief business officer
Edwin Moses, CEO of Ablynx, said: “Markus brings extensive experience in leading business development teams and executing licensing deals and acquisitions.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
- PHE study finds people who have had COVID-19 can still transmit the virus
- Sinovac’s COVID-19 vaccine appears safe in older adults
- PHE study finds people who have had COVID-19 can still transmit the virus
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- New study identifies drugs that are safe to use in COVID-19 treatment
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Onyx Health Celebrates Its 10th Anniversary with Five New Hires
- Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Trial combining British and Russian COVID-19 vaccines could begin in February
- New Oxford research institute established to tackle antimicrobial resistance
- EU proposes vaccine-sharing mechanism with low-income countries
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
